Off the scrapheap of discarded drugs and on its way to becoming the most highly anticipated approval of 2024, Bristol Myers Squibb’s schizophrenia treatment Cobenfy (KarXT) has had an unusual odyssey ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results